Abstract 3387
Background
Patients undergoing haematopoietic stem cell transplantation (HSCT) are often hospitalised in protective isolation in order to reduce the risk of dangerous infection. However, they could experience isolation-related suffering, problems in relationships with others, and difficulties in relating to themselves. Oncology nurses might play an important role in mitigating perceived isolation and in providing emotional support. The aim of this study was to identify which factors can influence the level of emotional support from nurses perceived by patients with haematological malignancies undergoing HSCT in isolation.
Methods
A multicentre prospective study was conducted in 10 haematology centres of the Italian Group of stem cell transplant (GITMO). Emotional support from nurses was measured between day +7 and +9 post-transplant using the Scale Experiences on the Newcastle Satisfaction with Nurses Scale. Multiple linear regression analysis was performed.
Results
The participants were 186 adult patients receiving autologous (48%) or allogeneic (52%) HSCT in protective isolation. They were mainly male (61.6%) with a mean age of 50.1 (SD = 13.4; range=19-71). The regression model explained 23% of the total variance (p < .001) (Table). Sex, pain level, double room, satisfaction with information received before HSCT, and patients to nurse ratio were independently associated with emotional support from nurses.Table: CN56
Regression model predicting perceived emotional support from nurses (n = 186)
| β | 95% CI | P | |
|---|---|---|---|
| Sex (female) | .193 | (.056; .332) | .006 |
| Pain level | -.147 | (-.287; -.007) | .040 |
| First HSCT | .099 | (-.038; .234) | .158 |
| Double room | .242 | (.098; .378) | .001 |
| Satisfaction with info | .403 | (.264; .547) | <.001 |
| Patients to nurse | -.168 | (-.316; -.027) | .021 |
| P | <.001 |
Conclusions
Patients who reported high emotional support from nurses were female, with low pain, satisfied with information received, and hospitalised in double room in a ward with a low patients to nurse ratio. It is crucial to reduce the patients to nurse ratio in order to promote the role of nurses in providing emotional support.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Campus Bio-Medico di Roma University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1945 - Randomized Phase II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies.
Presenter: Christoph Heilig
Session: Poster Display session 3
Resources:
Abstract
3021 - Homogenisation of Leftover Surgical Tissue across multiple cancer types: a Feasibility Study (HoLST-F)
Presenter: Lavinia Spain
Session: Poster Display session 3
Resources:
Abstract
2882 - Safety, efficacy, and immune effects of intratumoral tilsotolimod in patients with refractory solid tumors: updated results from ILLUMINATE-101
Presenter: Hani Babiker
Session: Poster Display session 3
Resources:
Abstract
1950 - Phase 1 Dose Escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumors: Updated results
Presenter: Erkut Borazanci
Session: Poster Display session 3
Resources:
Abstract
2391 - A phase 1 study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
Presenter: Anna Spreafico
Session: Poster Display session 3
Resources:
Abstract
5692 - FPA150 (B7-H4 antibody) Phase 1 Update in Advanced Solid Tumors: Monotherapy and in Combination with Pembrolizumab
Presenter: Zev Wainberg
Session: Poster Display session 3
Resources:
Abstract
2416 - MG1124, a novel CEACAM1-targeted monoclonal antibody, has therapeutic potential as a combination partner of PD-1 inhibitors in NSCLC patients
Presenter: Eun Hee Lee
Session: Poster Display session 3
Resources:
Abstract
2661 - Tumor stroma targeting and modulation by OMTX705 ADC, a novel and potent immunotherapeutic treatment of solid tumors.
Presenter: Myriam Fabre
Session: Poster Display session 3
Resources:
Abstract
3681 - Durvalumab + monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC)
Presenter: May Cho
Session: Poster Display session 3
Resources:
Abstract
2664 - Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy
Presenter: Nicholas Mach
Session: Poster Display session 3
Resources:
Abstract